For AOE due to
P aeruginosa and S aureus
AOE, acute otitis externa.
For AOE due to P aeruginosa and S aureus
Just one dose,
right in your office
See the benefit of
thermosensitive
technology
IMPORTANT SAFETY INFORMATION
CONTRAINDICATIONS
OTIPRIO (ciprofloxacin otic suspension) 6% is contraindicated in patients with a history of hypersensitivity to ciprofloxacin, to other quinolones, or to any of the components of OTIPRIO.
WARNINGS AND PRECAUTIONS
Potential for Microbial Overgrowth: OTIPRIO may result in overgrowth of non-susceptible bacteria and fungi. If such infections occur, institute alternative therapy.
ADVERSE REACTIONS
Acute otitis externa clinical trial: Adverse reactions (incidence at least 2%) with OTIPRIO vs sham were: ear pruritus (2% vs 2%), headache (2% vs 1%), otitis media (2% vs 1%), and ear discomfort (2% vs 0%).
USE IN SPECIFIC POPULATIONS
Pediatric Use: The safety and effectiveness of OTIPRIO in infants below six months of age have not been established for the treatment of acute otitis externa.
INDICATIONS AND USAGE
OTIPRIO (ciprofloxacin otic suspension) 6% is a fluoroquinolone antibacterial indicated for the treatment of acute otitis externa in patients 6 months of age and older due to Pseudomonas aeruginosa and Staphylococcus aureus.
Please click link below for full Prescribing Information.
OTIPRIO is being marketed by ALK-Abelló, Inc. and Otonomy, Inc.
OTIPRIO is a registered trademark of Otonomy, Inc.
©2020 Otonomy, Inc. All rights reserved. OTI0243.1220